APOA1 and atherosclerosis: Transgenic mice that overexpress apoA-I and the infusion of apoA-I/phospholipid complexes in humans are associated with reduced progression or regression of atherosclerosis.7–9 These observations have suggested that HDL-C-raising therapies might be an effective way to reduce the residual risk of cardiovascular diseases in patients who are being treated with current therapies.